About Us

Nash Pharmaceuticals is a Canadian drug development company focusing on developing repurposed therapeutic drugs. Drug repurposing (also known as re-profiling, re-tasking or therapeutic switching) is the application of approved drugs and compounds to treat a different disease than what it originally developed for. Nash’s business model seeks to minimize investment and drug development risk by taking advantage of regulatory approved drugs and discovering alternative clinical uses by accelerating entry into phase II human clinical trials.

Key Advantages

The benefit of this approach to drug development is that if promising data is generated from early animal model research, the drug can often be moved immediately into phase II studies without having to do any preclinical work, since it has already been completed. Preclinical work is the highest risk phase of drug development and can take up to 8 years to complete. A phase II study provides the greatest opportunity for significant value creation for a drug development company.

Non –Alcoholic Steatohepatitis (NASH)

NASH is a serious condition in which fat accumulates in liver tissue in people who consume little or no alcohol. It is the most severe form of non-alcoholic fatty liver disease (NAFLD) which in some individuals can progress to fibrosis (scarring) and ultimately hepatocellular carcinoma (liver cancer).

Market Opportunity

According to a new report published by Allied Market Research, titled, Non-Alcoholic Steatohepatitis (NASH) Market, by Drug Type and Sales Channel: Global Opportunity Analysis and Industry Forecast, 20212025,” the global non-alcoholic steatohepatitis (NASH) market was valued at $1.17 Billion in 2017, and is expected to reach $21.4 Billion by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Nash Technology

Nash has identified up to two potential compounds, which statistically significantly reduced the NAFLD score in an industry standard animal model of NASH, one of which reduced the average NAFLD score greater than 2.5 points.

Chronic Kidney Disease (CKD)

CKD is a condition in which the kidneys are damaged or cannot filter blood as well as healthy kidneys, often as a result of fibrosis. Because of this, excess fluid and waste from the blood remain in the body and may cause other health problems. 30 million people or 15% of US adults are estimated to have CKD.

Market Opportunity

The global market for chronic kidney disease drugs continues to proliferate at a significant pace, driven by the increasing number of chronic kidney disease patients and the growing need of novel treatments to improve patients’ quality of life. The global chronic kidney disease drugs market stood at US$11.5B in 2015. Burgeoning at a CAGR of 3.60% between 2016 and 2024, the market’s opportunity is expected to reach US$15.8B by the end of 2024.

Nash Technology

Nash has identified up to three drug candidates that when tested in an industry standard mouse model of kidney fibrosis , statistically significantly reduced fibrosis scores to equivalent levels to Telmisartan, a known anti-fibrotic compound. One compound also demonstrated a statistically significant improvement in kidney function when compared to Telmisartan.

Inflammatory Bowel Disease (IBD)

Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of your digestive tract.. This condition causes long-lasting inflammation and sores (ulcers) in the innermost lining of your large intestine (colon) and rectum.

Market Opportunity

The global inflammatory bowel disease treatment market at US$10.52 B in 2016. Rising at a steady 2.6% CAGR between 2017 and 2025, the market is likely to value US$14.83 B by the end of 2025. In 2016, North America led the global IBD market, which is attributable to the rising incidence of the disease witnessed among men and women alike in the region. incidence of Ulcerative colitis and Crohn’s disease is high in US and Canada, which fuels the demand for IBD treatment in North America.

Nash Technology

Nash has identified two potential compounds that statistically significantly improved multiple disease related endpoints in an ulcerative colitis model compared to untreated animals. Both candidates appeared as effective as the known approved front-line therapy, 5-amino salicylic acid (5-ASA) in reducing disease severity,

Dr. Mark Williams

Chief Executive Officer

Education:

Bsc Biochemistry (Queen’s)
Phd Virology (University of Alberta)
MBA Finance (University of Manitoba)

Experience:

>12 Years in Biotech
Assisted In Raising >$30M for Diamedica (DMA.V)
Secured Analyst Coverage and KOLS For DMA.V
Assisted in Raising Valuation of DMA > $125M on 5 FTE
Repositioned 3 Drugs From Preclinical Studies Directly to Phase II Trials
Invented DM199 (Recombinant Protein) In Phase II Trials For Stroke & Kidney Disease